We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Respiratory Medicine

Journal Scan / Research · June 15, 2020

Ultra Low–Dose Rituximab as Add-On Therapy in Anti-MDA5–Positive Patients With Polymyositis/Dermatomyositis–Associated ILD

Respiratory Medicine

 

Additional Info

Disclosure statements are available on the authors' profiles:

Respiratory Medicine
Ultra-Low Dose Rituximab as Add-On Therapy in Anti-MDA5-Positive Patients With Polymyositis /Dermatomyositis Associated ILD
Respir Med 2020 May 16;[EPub Ahead of Print], MM Mao, S Xia, BP Guo, WP Qian, ZX Zheng, XM Penga, RC Chen, Q Luoa,Q Hana

Further Reading